- Home
- ACET vs MIST Comparison
ACET vs MIST Comparison
Compare ACET & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- MIST
- Stock Information
- Founded
- ACET 1947
- MIST 2003
- Country
- ACET United States
- MIST Canada
- Employees
- ACET N/A
- MIST N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- MIST Health Care
- Exchange
- ACET Nasdaq
- MIST Nasdaq
- Market Cap
- ACET 83.2M
- MIST 98.1M
- IPO Year
- ACET N/A
- MIST N/A
- Fundamental
- Price
- ACET $0.89
- MIST $1.91
- Analyst Decision
- ACET Buy
- MIST Strong Buy
- Analyst Count
- ACET 6
- MIST 2
- Target Price
- ACET $6.00
- MIST $17.00
- AVG Volume (30 Days)
- ACET 414.2K
- MIST 2.3M
- Earning Date
- ACET 03-06-2025
- MIST 03-13-2025
- Dividend Yield
- ACET N/A
- MIST N/A
- EPS Growth
- ACET N/A
- MIST N/A
- EPS
- ACET N/A
- MIST N/A
- Revenue
- ACET N/A
- MIST N/A
- Revenue This Year
- ACET N/A
- MIST N/A
- Revenue Next Year
- ACET N/A
- MIST $1,105.43
- P/E Ratio
- ACET N/A
- MIST N/A
- Revenue Growth
- ACET N/A
- MIST N/A
- 52 Week Low
- ACET $0.74
- MIST $1.12
- 52 Week High
- ACET $2.43
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- ACET 55.27
- MIST 51.87
- Support Level
- ACET $0.74
- MIST $1.87
- Resistance Level
- ACET $0.81
- MIST $2.50
- Average True Range (ATR)
- ACET 0.06
- MIST 0.22
- MACD
- ACET 0.01
- MIST 0.01
- Stochastic Oscillator
- ACET 71.29
- MIST 47.11
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).